TY - JOUR
T1 - Antiangiogenic strategies in neuroblastoma
AU - Ribatti, Domenico
AU - Ponzoni, Mirco
PY - 2005/2
Y1 - 2005/2
N2 - Promising new antiangiogenic strategies are emerging for the treatment of cancer and the inhibition of angiogenesis could represent a powerful adjunct to traditional therapy of malignant tumors. Over the last ten years several reports have been published concerning the relationship between tumor progression and angiogenesis in neuroblastoma in experimental models in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with poor prognosis, suggesting dependence of aggressive tumor growth on active angiogenesis. Here, we present an overview of recent advances in antiangiogenesis in neuroblastoma and describe the most important active substances, preclinical and clinical data, as well as future pespectives.
AB - Promising new antiangiogenic strategies are emerging for the treatment of cancer and the inhibition of angiogenesis could represent a powerful adjunct to traditional therapy of malignant tumors. Over the last ten years several reports have been published concerning the relationship between tumor progression and angiogenesis in neuroblastoma in experimental models in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with poor prognosis, suggesting dependence of aggressive tumor growth on active angiogenesis. Here, we present an overview of recent advances in antiangiogenesis in neuroblastoma and describe the most important active substances, preclinical and clinical data, as well as future pespectives.
KW - Antiangiogenesis
KW - Neuroblastoma
KW - Tumor progression
UR - http://www.scopus.com/inward/record.url?scp=13844272288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13844272288&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2004.09.006
DO - 10.1016/j.ctrv.2004.09.006
M3 - Article
C2 - 15707702
AN - SCOPUS:13844272288
SN - 0305-7372
VL - 31
SP - 27
EP - 34
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 1
ER -